CD274 and neoplasm: Thus, the first clinical studies with Nivolumab in a wide spectrum of tumors[60] found that response to checkpoint inhibitors were restricted to patients who expressed PD-L1, while patients without PD-L1 tumor expression were frequently unresponsive.